But why did Rothman get it wrong? The most obvious explanation is that he did it on purpose. His alarmist tone, in a high-profile editorial in the top medical journal in the US, was aimed at drawing attention to unreasonable ethical guidelines, as well as the rampant 'legalization' in US culture. It is not devoid of irony, however, that Rothman himself has fulfilled his prophecy by providing expert advice in legal battles-for example, his controversial roles in a suit involving Texaco and indigenous groups in Ecuador, 3 and in challenging the need for extra scrutiny for pharmaceutical-industry funded trials. 4 Whether or not Rothman got it wrong on purpose, there are at least two additional explanations for the failed prediction. The first is that his definition of epidemiology was too narrow. The second that his definition of the world was too narrow.
A strict definition of epidemiology would be the study of exposure-outcome relationships, with an emphasis on biological, chemical and physical agents. Accepting this definition, one might conceive that after a certain point future progress will be limited because most important relationships will have been identified. 5 For example, one may argue that all major risk factors for lung cancer have already been recognized. New epidemiological findings would then depend on either the emergence of new exposures or diseases, or else on improvements in the measurement of diseases, exposures or susceptibility. Even if a narrow definition of epidemiology is adopted, Rothman may have underestimated its potential for future development. Fortunately, epidemiology has grown well beyond the study of such proximate agents of disease. Social and behavioural sciences increasingly contribute to epidemiological studies on 'the causes of the causes', for example, why do some people smoke or overeat while others do not. [5] [6] [7] Epidemiological tools are increasingly used for impact evaluation 8, 9 and burden of disease estimations, 9 among many other applications.
In particular, Rothman's diatribe was centred on barriers imposed by multiple institutional review boards involved in studies that required the participation of a large number of hospitals-for example, collaborative case-control studies. However, these only account for a fraction of all epidemiological studies. Such restrictions do not affect cross-sectional surveys, nor case-control or cohort studies in countries with a health information system that pools data from multiple institutionsas is the case for several countries outside the USA.
This leads us to the second reason for the wrongful prediction: the paper is utterly USA-centred. After the brief reference to Graunt and Farr, Rothman overlooks developments outside the USA. At the time when the commentary was written, major epidemiological investigations, in particular cohort studies, were well under way in Northern Europe. Ethical regulations have become stricter throughout the world-fortunately so!-but this has not significantly hindered large-scale studies. Also fortunately, legal action does not seem to constitute a major threat to research outside the USA.
In particular, epidemiological studies have markedly increased in Latin America and Asia, firstly with important contributions of researchers from North America and Europe, but in the last couple of decades with a steadily growing participation of local scientists. For example, our last national epidemiological conference in Brazil attracted over 4000 participants. Many studies on infectious and nutritional epidemiology are under way in Africa, mainly on AIDS and malaria; although these investigations are still mostly led by expatriates, African scientists are building up their own research centres and networks.
I am not sufficiently familiar with the situation in the USA to gauge whether Rothman's article had a major impact. It received a modest 36 citations in the Web of Science since its publication, and the only letter that appeared in the following issues of the New England Journal of Medicine was from Alvan Feinstein, who challenged the contribution of William Farr to epidemiology because of his backing of the miasma theory. 10 Hardly a topic of current interest! Futurology is a high-risk occupation. Again with the benefit of hindsight, looking at Rothman's paper after a quarter century shows that ethical guidelines helped improve epidemiology, and that our discipline evolved much beyond the study of proximate exposures and of hospital-based studies. Long live epidemiology!
